Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion

Abstract

INTERCEPT-CPAs were well tolerated in a broad range of patients, including infants. ATR incidence was low and when present ATRs were of mild severity.

Photochemical Inactivation of Chikungunya Virus in Human Apheresis Platelet Components by Amotosalen and UVA Light

“…68 This theory was put into practice during the La Réunion outbreak when, in 2006, French authorities implemented mandatory photochemical treatment of platelet components with the INTERCEPT Blood System to reduce the risk of CHIKV transmission on La Réunion. 32 Approximately 4,000 platelet units were administered over the course of 1 year, and no transfusion related CHIKV transmissions were documented. Although pathogen inactivation obviously adds cost to blood components, in the context of the current testing paradigm and assuming that there is no established nucleic acid test assay for a specific pathogen, it has been found that pathogen inactivation is more cost effective than NAT in terms of quality-adjusted life years, a measurement of clinical and cost effectiveness.…”

“…However, the 5-day shelf life of platelet components precluded their being delivered to La Réunion from France and pathogen inactivation was instituted on an emergency basis to provide safe platelets for patients there. 32 The relatively short duration of the viremic period (6-7 days) and low rates of asymptomatic infections (3% to 25%) [34][35][36] have been proposed as factors that decrease the risk of contamination of donated blood with CHIKV.…”

“…1 Thus, during the Italian CHIKV outbreak of 2007 and the 2005-2006 epidemic in the French island La Réunion, all blood collections were suspended, [31][32][33] and the required blood was delivered from unaffected regions of Italy or continental France. However, the 5-day shelf life of platelet components precluded their being delivered to La Réunion from France and pathogen inactivation was instituted on an emergency basis to provide safe platelets for patients there.…”

Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions

“…This was done with photochemical treatment by Amotosalem and UVA, a technology that is efficient against the vast majority of known pathogens and which might also prevent the transmission of unknown pathogens (25,(38)(39)(40)(41) INTERCEPT technology is routinely used for PI of PLTs and plasma for clinical use as it is able to inactivate a wide spectrum of bacteria, viruses, and parasites, as well as contaminating leukocytes (42)(43)(44)(45)(46). INTERCEPT process and nucleic acids targeting PI technology is not, however, effective against prion diseases, therefore the risk of prion transmission by treated lysates would remain.…”

Model Calculations to Quantify Clinical and Economic Effects of Pathogen Inactivation in Platelet Concentrates

“…Present examples for pathogens transmissible by blood transfusions requiring additional safety measures are the West Nile virus (WNV), severe acute respiratory syndrome (SARS) virus, Dengue virus, Chikungunya virus, and the parasites Trypanosoma cruzi (Chagas disease), Plasmodium falciparum (malaria) and Babesia spp. (babesiosis) [9,10,11]. Table 1 gives an overview of the haemovigilance data of 3 European countries derived from the literature.…”